Portugal Colonial - Bayer profit up but glyphosate sales struggle

Core profit rose nine percent to 4.45 billion euros ($5.22 billion), with profits at the agricultural division up almost 18 percent, boosted by the resolution of a licensing dispute and higher corn and soybean seed sales.

Herbicide revenue at the division struggled, however, with sales of glyphosate-based products falling 15.1 percent.

Bayer has spent more than $10 billion settling thousands of cases linked to glyphosate since it acquired the US agrichemical group Monsanto in 2018, developer of the popular herbicide Roundup.

The company is hoping that the US Supreme Court will provide some relief in a case involving a Missouri man who says Roundup is responsible for his blood cancer.

Bayer has argued that it should be immune from lawsuits in US state courts since the country's Environmental Protection Agency (EPA) approved the sale of Roundup without any cancer warning label.

Bayer proposed in February a $7.25-billion deal to settle outstanding cases with hopes of final approval by late June, but appeals could follow.

"We believe we still have the opportunity to significantly contain litigation this year, with or without the Supreme Court ruling," Bayer's chief executive Bill Anderson said.

"That being said, the Supreme Court ruling is really a big sign for the future because, frankly, it just opens the question of, well, what is a pesticide label in the US? If there's no federal pre-emption, then what is the point of a federally approved label?" he said.

The International Agency for Research on Cancer considers glyphosate a probable human carcinogen.

Bayer has pointed to scientific studies as well as regulatory approvals in the US and the European Union as evidence the weedkiller is safe.

But customers in North America, Europe, the Middle East and Africa are "delaying purchases" of glyphosate products, Bayer said in its report.

With May 23 marking the 10th anniversary of Bayer announcing its plan to buy Monsanto, Anderson was asked what he made of the deal.

"I don't think there's really anything to say about that," he said. "Obviously, the financial terms, in hindsight, didn't work out very well."

N.Esteves--PC